Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PYGB | P11216 | 3/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045987 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL17117588 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL15853521 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL18333522 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL20045968 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL24454399 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL15142882 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL15905650 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL16359157 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA | |
| SCHEMBL15142802 | 1.00 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1PYGBOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | ALDH1A1 2009/4885THRB 282/4885MAPK1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.